The Food and Drug Administration on Wednesday granted approval for Gilead Sciences’ twice-yearly injectable HIV prevention medication, a milestone that the company and some epidemiologists have said could be a monumental step toward ending the decadeslong HIV/AIDS epidemic. 

The new medication, which will be marketed as Yeztugo, is an injectable HIV pre-exposure prophylaxis, or PrEP, making it a much more convenient and accessible tool for HIV prevention than existing oral medications.